Answers are grounded in this paper and cite their sources.
Background: Lung cancer is a significant public health concern in Mexico, being a leading cause of oncological mortality worldwide. Objective: This study aims to analyze real-world data from the Mexican Society of Clinical Oncology database to assess the characteristics and systemic treatment patterns of surgically treated patients with resectable Stages IB, II, and IIIA (early stages) non-small cell lung cancer (NSCLC) in Mexico. Materials and methods: Retrospective non-interventional analysis utilized data from patients who underwent surgery for early stages NSCLC. Descriptive statistics were used for analysis. Results: The study included 105 patients, 75.96% with adenocarcinoma and 21.15% with epidermoid carcinoma. Most patients (66.34%) had Stage IIIA NSCLC, followed by Stage I (19.23%). Age distribution was similar between genders in the 50-69-year age group. Patients with squamous histology had higher smoking indices and asbestos exposure. Chemotherapy, particularly paclitaxel and carboplatin combination, was the primary systemic treatment used in both adjuvant and neo-adjuvant settings for both histologies. Conclusion: Chemotherapy remains the primary systemic treatment approach for surgically-treated patients with resectable Stages IB, II, and IIIA NSCLC in Mexico. Innovative therapies are needed.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐Cid et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: